Rexahn Pharmaceuticals, Inc. (REXN)

[sons4]

From Simon Monger's 6/16 Column

Rexahn Pharmaceuticals Inc. (RNN, Free Analysis), a clinical stage biopharmaceutical company focused on cancer and CNS diseases, was initiated with a Buy rating and $3.00 per share price target by Brean Murray ahead of the opening bell. At a significant 144% premium to the current market price, the analyst’s price target reflects a very bullish stance on the company’s future outlook.

While the stock has been beaten down in recent months by Dr. Chang Ahn’s decision to step down from CEO and a recent dilutive capital raise, the biopharmaceutical company has made considerable progress in advancing its clinical trials and Ahn has been increasing his stake in the company. As a result, this is one stock that is potentially misunderstood by the market and could be a bargain at these levels.